• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Blenrep Combo Accepted for FDA Review in R/R Multiple Myeloma

by | Dec 3, 2024 | Uncategorized

Source: CureToday articles The FDA has accepted a biologics license application for Blenrep plus bortezomib or pomalidomide for patients with relapsed or refractory multiple myeloma. Read More

Blenrep-Based Combo Provides Survival Benefit in Relapsed/Refractory Multiple Myeloma

by | Nov 18, 2024 | Uncategorized

Source: CureToday articles Findings from a phase 3 trial with Blenrep, Velcade and dexamethasone in relapsed/refractory multiple myeloma will be presented at an upcoming conference. Read More

Triplet regimen extends OS in relapsed or refractory multiple myeloma

by | Nov 14, 2024 | Uncategorized

A triplet regimen extended OS compared with the current standard of care for patients with relapsed or refractory multiple myeloma, according to a topline data announcement.Patients with multiple myeloma often become refractory to first-line triplet or quadruplet...

QOL a Crucial Consideration During R/R Myeloma Treatment Decision-Making

by | Nov 12, 2024 | Uncategorized

Source: CureToday articles Patients with relapsed or refractory multiple myeloma should consider quality of life with survival when choosing the most suitable treatment option. Read More

FDA Receives Application Seeking Approval of Darzalex Faspro in Smoldering Myeloma

by | Nov 11, 2024 | Uncategorized

Source: CureToday articles If approved by the FDA, Darzalex Faspro may be the first treatment for smoldering multiple myeloma as compared to treating the disease once it progresses. Read More

KRd56 Versus KRd27 Shows Similar Effectiveness, Safety in R/R Multiple Myeloma

by | Nov 7, 2024 | Uncategorized

Source: CureToday articles In patients with relapsed or refractory multiple myeloma, KRd56 and KRd27 showed similar effectiveness and safety, but other treatment options may be better. Read More
« Older Entries

Recent Content

  • Blenrep Combo Accepted for FDA Review in R/R Multiple Myeloma
  • Multiple myeloma long-term survivors exhibit sustained immune alterations decades after first-line therapy
  • High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis
  • CAR-T cell therapy in Multiple Myeloma: current status and future challenges
  • Belantamab Mafodotin Achieves Secondary End Point for Treatment of Relapsed, Refractory Multiple Myeloma
  • Efficacy and safety of daratumumab for the treatment of refractory/relapsed multiple myeloma. A systematic review of meta-analyses
  • Cell surface marker heterogeneity in human myeloma cell lines for modeling of disease and therapy
  • A systematic review on the epidemiology and treatment options of multiple Myeloma in Asia
  • Blenrep-Based Combo Provides Survival Benefit in Relapsed/Refractory Multiple Myeloma
  • A systematic literature review on clonal evolution events preceding relapse in multiple myeloma
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT